A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Dose (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZM-H1505R
Latest Information Update: 17 Jan 2022
At a glance
- Drugs Canocapavir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Shanghai Zhimeng Biopharma
Most Recent Events
- 12 Nov 2021 According to a Zhimeng Biopharma media release, the results of this study will be presented in EASLs 2022 International Liver Congress
- 11 Oct 2021 According to a Zhimeng Biopharma media release, results from this trial will be presented in the upcoming 2021 annual meeting of the America Association for the Study of Liver Diseases (AASLD).
- 11 Oct 2021 Results published in the Zhimeng Biopharma Media Release.